<DOC>
	<DOC>NCT00092404</DOC>
	<brief_summary>The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.</brief_summary>
	<brief_title>Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)</brief_title>
	<detailed_description>The duration of treatment is 6 weeks.</detailed_description>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy children 12 to 18 months of age History or prior exposure to measles, mumps, or rubella History of allergic reactions to any component of the vaccines as evaluated by the study doctor</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>